<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105987">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02030262</url>
  </required_header>
  <id_info>
    <org_study_id>C13-10-1231</org_study_id>
    <nct_id>NCT02030262</nct_id>
  </id_info>
  <brief_title>Study of Impact of Air vs SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping</brief_title>
  <official_title>Study of the Impact of Air Versus SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Québec, CHU de Québec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Québec, CHU de Québec</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if one of these gaz (air and sulfur hexafluoride)
      is better than the other in epiretinal membrane peeling surgery. Both are already used for
      this surgery and this study will tell us if one is better than the other.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">438</enrollment>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>Air</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will undergo epiretinal membrane peeling with fluid-air exchange. The remaining of the surgery is the same in all arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfur hexafluoride (SF6)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant will undergo epiretinal membrane peeling with fluid-SF6 exchange. The remaining of the surgery will stay the same.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Epiretinal membrane peeling with fluid-air exchange</intervention_name>
    <description>The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.</description>
    <arm_group_label>Air</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Epiretinal membrane peeling with fluid-SF6 exchange</intervention_name>
    <description>The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.</description>
    <arm_group_label>Sulfur hexafluoride (SF6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of epiretinal membrane with corresponding optical coherence
             tomography

          -  ETDRS visual acuity worse or equal to 20/30

          -  Adult able to give consent

        Exclusion Criteria:

          -  Diagnosis of age-related macular degeneration

          -  Opacity blocking the fundus visualisation

          -  Presence of active intraocular inflammation

          -  Presence of intraocular tumor

          -  Presence of retinal detachment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu Caissie, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du CHU de Québec; Université Laval</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement, CHU de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
